28 Jul 2023

Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA

Immuno Cure BioTech (“Immuno Cure”), a biotechnology group based in the Hong Kong Science Park, is pleased to announce today that it has closed the US$12 million tranche in the US$27 million Series A fundraising round.

Key Takeaways

  • HKSTP’s Park company Immuno Cure plans to use the fundraising to speed up the development of DNA vaccines and antibodies, and to prepare for an IPO in Hong Kong.
  • The Company focuses on research and development of immunotherapies for cancers, inflammatory and infectious diseases, with two DNA vaccine candidates currently in clinical trials.
  • Gobi Partners GBA led the fundraising round and believes that Immuno Cure’s technologies have the potential to truly change the world.